Teikoku Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Teikoku Pharma USA, founded in 1999, is a commercial-stage biopharmaceutical company with deep expertise in transdermal drug delivery systems. The company leverages its proprietary Hydrohesive® and Matrix patch technologies to develop non-opioid pain management solutions and treatments for CNS disorders, with a pipeline featuring late-stage assets like TPU-006 for post-surgical pain. With a marketed product generating revenue and a strategic focus on global partnerships and licensing, Teikoku is positioned to address significant unmet needs in pain management and neurology.

Pain ManagementCNS DisordersDermatologyOncology

Technology Platform

Proprietary transdermal drug delivery technologies including Hydrohesive® and Matrix patch systems, enabling continuous drug delivery for 1-7 days.

Opportunities

The global push for non-opioid pain solutions creates a massive market opportunity for TPU-006.

Additionally, the aging population drives demand for novel, non-oral treatments for CNS disorders like Alzheimer's agitation, where TPU-030 and the approved ALLYDONE patch compete.

Risk Factors

Key risks include clinical failure of late-stage pipeline assets like TPU-006, regulatory hurdles despite Fast Track status, and intense competition in the non-opioid pain and Alzheimer's markets.

Revenue dependence on the mature Lidoderm franchise is also a concentration risk.

Competitive Landscape

Teikoku competes in transdermal pain with other patch makers and broadly with all non-opioid analgesic developers (e.g., Vertex's VX-548). In CNS transdermals, it competes with existing patches like Exelon and Neupro, and a wide array of Alzheimer's therapies. Its proprietary delivery technology and focus on multi-day wear provide differentiation.

More companies in Drug Delivery & Formulation →More companies in United States →